A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

被引：24

作者：

Wainberg, Zev ^{[1
]}

Hecht, J. Randolph ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, GI Oncol Program, Los Angeles, CA 90095 USA

来源：

CLINICAL COLORECTAL CANCER | 2006年 / 5卷 / 05期

关键词：

epidermal growth factor receptor; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin; vascular endothelial growth factor;

D O I：

10.3816/CCC.2006.n.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：363 / 367

页数：5

共 26 条

[1]

BERLIN J, 2004, 9 ANN M EUR SOC MED

[2]

COHEN RB, 2000, P AN M AM SOC CLIN, V19, pA474

[3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[4]

FIGLIN RA, 2002, P AN M AM SOC CLIN, V21, pA10

[5]

Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S

[6]

Hochster HS, 2005, J CLIN ONCOL, V23, p249S

[7] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[8]

*IMCLONE SYST INC, 2005, ERB PACK INS

[9]

Jemal A, 2005, CA-CANCER J CLIN, V55, P259

[10] Cancer statistics, 2005 [J].

Jemal, A ;

Murray, T ;

Ward, E ;

Samuels, A ;

Tiwari, RC ;

Ghafoor, A ;

Feuer, EJ ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30

← 1 2 3 →